Quantcast

ImaginAb Reaches ImmunoOncology License&Clinical Trial Collaboration With Nektar


Shutterstock photo

ImaginAb Reaches ImmunoOncology License&Clinical Trial Collaboration With Nektar


(RTTNews.com) - ImaginAb Inc., an immuno-oncology imaging company, announced that it has entered into a non-exclusive license and clinical trial collaboration with Nektar Therapeutics ( NKTR ). Financial terms of the agreement were not disclosed.

As per the terms of the agreement, Nektar will use ImaginAb's CD8 ImmunoPET technology to measure whole body and tumor CD8+ T cells' density and distribution in cancer patients. The collaboration will provide important mechanistic insight into various candidates in Nektar's immuno-oncology portfolio.

"Our goal is to help companies accelerate the research and development of next-generation cancer immunotherapies, so clinicians can treat cancer patients more effectively," said Martyn Coombs, Chief Executive Officer of ImaginAb.


Read the original article on RTTNews (http://www.rttnews.com/2966622/imaginab-reaches-immunooncology-license-clinical-trial-collaboration-with-nektar.aspx)


For comments and feedback: contact editorial@rttnews.com






This article appears in: World Markets , Stocks
Referenced Symbols: NKTR



More from RTT News

Subscribe






See All RTT news











Research Brokers before you trade

Want to trade FX?